5
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Platforms and Artificial Intelligence in Dementia

      Submit here by August 31, 2025

      About Dementia and Geriatric Cognitive Disorders: 2.2 Impact Factor I 4.7 CiteScore I 0.809 Scimago Journal & Country Rank (SJR)

      Call for Papers: Cancer Biology and Therapy

      Submit here by August 31, 2025

      About Cytogenetic and Genome Research: 1.7 Impact Factor I 3.1 CiteScore I 0.385 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nonfamilial Bilateral Synchronous Renal Cell Carcinoma with Discordant Histology with Eventual Complete Response to Dual Immunotherapy

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bilateral synchronous renal cell carcinoma (RCC) is rare, especially in sporadic rather than familial cases. While immunotherapy has improved prognosis, RCC remains a diagnosis with significant morbidity and mortality, particularly pronounced in patients with sarcomatoid RCC (sRCC). We describe a case of a patient with bilateral, synchronous, nonfamilial RCC, with and without sarcomatoid features and differing genetic markers, who demonstrated a pathologic response after neoadjuvant nivolumab and ipilimumab. The patient then had radical left nephrectomy and partial right nephrectomy followed by adjuvant nivolumab and cabozantinib, after which the patient had no evidence of disease. Our patient’s illustrative case shows the potential therapeutic value of immunotherapy even in sRCC, the disease’s most aggressive clinical subtype.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

          The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

            The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Immunotherapy in Renal Cell Carcinoma: The Future Is Now

              Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.
                Bookmark

                Author and article information

                Journal
                Case Rep Oncol
                Case Rep Oncol
                CRO
                CRO
                Case Reports in Oncology
                S. Karger AG (Basel, Switzerland )
                1662-6575
                13 November 2023
                Jan-Dec 2023
                13 November 2023
                : 16
                : 1
                : 1378-1383
                Affiliations
                [a ]Department of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD, USA
                [b ]Department of Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, MD, USA
                Author notes
                Correspondence to: Ian J. Robertson, ianrobertson415@ 123456gmail.com
                Article
                533936
                10.1159/000533936
                10642977
                37965647
                6ec098d4-d680-4790-8841-00e014b704c0
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 22 April 2023
                : 31 August 2023
                : 2023
                Page count
                Figures: 1, Tables: 1, References: 16, Pages: 6
                Funding
                No funding sources were used.
                Categories
                Case Report

                Oncology & Radiotherapy
                case report,renal cell carcinoma,immunotherapy
                Oncology & Radiotherapy
                case report, renal cell carcinoma, immunotherapy

                Comments

                Comment on this article